8-K: NRC Health Q4 2025 Earnings Decline Amid Revenue Drop

NRC Health reported a significant decline in GAAP net income and revenue for both the fourth quarter and full-year 2025, despite an 8% year-over-year increase in Total Recurring Contract Value (TRCV).

Summary

• Total revenue for the fourth quarter ended December 31, 2025, was $35.2 million, which was reported as up 2% quarter-over-quarter, but represents a 4.6% decrease from $36.9 million in Q4 2024.
• GAAP net income for Q4 2025 was $1.8 million, representing 5% of revenue, a 72.7% decrease from $6.6 million in Q4 2024.
• Adjusted Net Income for Q4 2025 was $3.4 million, representing 10% of revenue, a 49.3% decrease from $6.7 million in Q4 2024.
• Adjusted EBITDA for Q4 2025 was $8.7 million, representing 25% of revenue, a 23.1% decrease from $11.3 million in Q4 2024.
• GAAP net income per fully diluted share for Q4 2025 was $0.08, while Adjusted net income per diluted share was $0.16.
• Net cash from operating activities for Q4 2025 increased 13% year-over-year to $7.2 million, representing 20% of revenue.
• Total Recurring Contract Value (TRCV) reached $144.1 million, an 8% increase year-over-year, and grew sequentially for the fifth consecutive quarter.
• Full-year 2025 total revenue was $137.4 million, a 4.0% decrease from $143.1 million in 2024.
• Full-year 2025 GAAP net income was $11.6 million, representing 8% of revenue, a 53.2% decrease from $24.8 million in 2024.
• Full-year 2025 Adjusted Net Income was $20.7 million, representing 15% of revenue, a 17.2% decrease from $25.0 million in 2024.
• Full-year 2025 Adjusted EBITDA was $40.2 million, representing 29% of revenue, a 3.4% decrease from $41.6 million in 2024.
• Full-year 2025 GAAP net income per fully diluted share was $0.50, while Adjusted net income per diluted share was $0.93.
• Full-year 2025 net cash from operating activities was $26.5 million, representing 19% of revenue, a 23.4% decrease from $34.6 million in 2024.
• The Board of Directors declared a quarterly cash dividend of $0.16 per share, payable on April 10, 2026, to shareholders of record as of March 27, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative report. While TRCV growth and Q4 operating cash flow are positive, the substantial year-over-year declines in GAAP net income, adjusted net income, and overall revenue for both the quarter and full year indicate significant challenges.

Positives

• Total Recurring Contract Value (TRCV) increased 8% year-over-year to $144.1 million, indicating strong customer retention and recurring revenue streams.
• TRCV grew sequentially for the fifth consecutive quarter, demonstrating consistent operational momentum.
• Net cash from operating activities for Q4 2025 increased 13% year-over-year to $7.2 million, showing improved short-term cash generation.
• The company declared a quarterly cash dividend of $0.16 per share, signaling confidence in future cash flows and commitment to shareholder returns.

Negatives

• Q4 2025 GAAP Net Income decreased significantly by 72.7% year-over-year to $1.8 million from $6.6 million in Q4 2024.
• Q4 2025 Adjusted EBITDA decreased by 23.1% year-over-year to $8.7 million from $11.3 million in Q4 2024.
• Full-year 2025 GAAP Net Income decreased by 53.2% year-over-year to $11.6 million from $24.8 million in 2024.
• Full-year 2025 total revenue decreased by 4.0% year-over-year to $137.4 million from $143.1 million in 2024.
• Full-year 2025 net cash from operating activities decreased by 23.4% year-over-year to $26.5 million from $34.6 million in 2024.
• Selling, General and Administrative expenses increased from $11.452 million in Q4 2024 to $14.444 million in Q4 2025, and from $44.911 million in FY 2024 to $54.805 million in FY 2025.
• Interest expense significantly increased from $729 thousand in Q4 2024 to $1.370 million in Q4 2025, and from $2.595 million in FY 2024 to $4.762 million in FY 2025.

Risks

• Actual results or events may differ from those anticipated by forward-looking statements due to significant risks and uncertainties, some of which cannot be predicted or quantified.
• Future events and actual results could differ materially from forward-looking statements, as detailed in the Risk Factors section of the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings.

Future Outlook

The company's management expresses confidence in a strong foundation for continued execution, emphasizing their mission to turn human understanding into meaningful, measurable action as healthcare leaders navigate complexity. The declaration of a future dividend payment also indicates a positive outlook on future cash flow and shareholder returns.

Management Comments

• "Our fourth quarter results reflect the strong, disciplined execution happening across NRC Health and the deep trust our customers place in us."
• "With TRCV reaching $144 million and momentum building across our portfolio, we finished the year with a strong foundation for continued execution."
• "As healthcare leaders navigate unprecedented complexity, our mission—turning human understanding into meaningful, measurable action—has never been more essential."
• "I’m incredibly proud of our teams and energized by the opportunity ahead as we continue helping our partners elevate the experiences of the people they serve."

Industry Context

StockSavvy.ai notes that NRC Health operates in the healthcare experience improvement solutions sector, a market increasingly vital as healthcare providers face growing demands for patient satisfaction and operational efficiency. The company's focus on 'human understanding' aligns with broader industry trends emphasizing patient-centric care and data-driven insights. While TRCV growth indicates strong recurring revenue, the overall decline in GAAP net income and revenue suggests potential headwinds or increased investment in a competitive landscape where digital health and patient engagement platforms are rapidly evolving.

Comparison to Industry Standards

• NA. The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. A detailed industry comparison would require external data on competitors such as Press Ganey, Health Catalyst, or Qualtrics' healthcare offerings, which are not included in this filing.

Stakeholder Impact

• Shareholders: Will receive a quarterly dividend of $0.16 per share. However, significant declines in GAAP and Adjusted Net Income and EPS may negatively impact shareholder value and future investment decisions.
• Customers: Continued growth in TRCV and management's emphasis on 'human understanding' suggest ongoing commitment to customer satisfaction and retention in healthcare experience improvement solutions.
• Employees: Management expresses pride in their teams, indicating a focus on employee contribution, though no specific impact on employees is detailed.

Next Steps

• Host a conference call on February 3, 2026, at 4:30 p.m. ET to discuss the financial results.
• Pay a quarterly cash dividend of $0.16 per share on April 10, 2026, to shareholders of record as of March 27, 2026.

Key Dates

Recommendation

The substantial year-over-year declines in GAAP net income (72.7% in Q4, 53.2% for full year), adjusted net income, and overall revenue indicate significant operational and profitability challenges. While TRCV growth is positive, it is overshadowed by the deterioration in core financial performance and increased operating and interest expenses. The dividend declaration offers some stability but does not offset the underlying weakness, suggesting a 'sell' recommendation for investors seeking growth and strong profitability.

Keywords

NRC Health, National Research Corporation, Healthcare Technology, Financial Results, Q4 2025, Full-Year 2025, Earnings, TRCV, Adjusted EBITDA, Healthcare Experience, Patient Experience, Dividend